Online inquiry

IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3903MR)

This product GTTS-WQ3903MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3903MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11072MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ6904MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ14912MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ5129MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ11853MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ5597MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ10174MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ6052MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW